CA2792392C - The use of amisulpride as an anti-emetic - Google Patents

The use of amisulpride as an anti-emetic Download PDF

Info

Publication number
CA2792392C
CA2792392C CA2792392A CA2792392A CA2792392C CA 2792392 C CA2792392 C CA 2792392C CA 2792392 A CA2792392 A CA 2792392A CA 2792392 A CA2792392 A CA 2792392A CA 2792392 C CA2792392 C CA 2792392C
Authority
CA
Canada
Prior art keywords
amisulpride
use according
vomiting
administration
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2792392A
Other languages
English (en)
French (fr)
Other versions
CA2792392A1 (en
Inventor
Julian Clive Gilbert
Robert William Gristwood
Nicola Cooper
Gabriel Fox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acacia Pharma Ltd
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2792392(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of CA2792392A1 publication Critical patent/CA2792392A1/en
Application granted granted Critical
Publication of CA2792392C publication Critical patent/CA2792392C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2792392A 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic Active CA2792392C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1004020.2 2010-03-11
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
PCT/GB2011/050472 WO2011110854A2 (en) 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic

Publications (2)

Publication Number Publication Date
CA2792392A1 CA2792392A1 (en) 2011-09-15
CA2792392C true CA2792392C (en) 2018-06-19

Family

ID=42136792

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2792392A Active CA2792392C (en) 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic

Country Status (26)

Country Link
US (12) US9084765B2 (enExample)
EP (3) EP2796171B1 (enExample)
JP (2) JP5886213B2 (enExample)
KR (1) KR101738201B1 (enExample)
CN (1) CN102892407B (enExample)
AU (1) AU2011225898B2 (enExample)
BR (1) BR112012022746B1 (enExample)
CA (1) CA2792392C (enExample)
CY (3) CY1115487T1 (enExample)
DK (3) DK2796171T3 (enExample)
EA (1) EA030335B1 (enExample)
ES (3) ES2665418T3 (enExample)
GB (1) GB201004020D0 (enExample)
HR (3) HRP20140744T1 (enExample)
HU (1) HUE037088T2 (enExample)
IL (1) IL221746A (enExample)
LT (1) LT2796171T (enExample)
MX (3) MX388787B (enExample)
NO (1) NO2796171T3 (enExample)
NZ (1) NZ602279A (enExample)
PL (3) PL2796171T3 (enExample)
PT (3) PT2796171T (enExample)
RS (3) RS53466B (enExample)
SI (3) SI2544657T1 (enExample)
SM (3) SMT201800188T1 (enExample)
WO (1) WO2011110854A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
JP2018530744A (ja) 2015-09-02 2018-10-18 カリフォルニア インスティチュート オブ テクノロジー 低濃度の硫化水素ガスの分光学的検出のための方法および装置
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
US20220323409A1 (en) * 2019-06-04 2022-10-13 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
MX2021014774A (es) 2019-06-04 2022-02-03 Sunovion Pharmaceuticals Inc Formulaciones de liberacion modificada y usos de las mismas.
CA3148042A1 (en) * 2019-07-31 2021-02-04 Astellas Pharma Inc. Pharmaceutical composition for otic administration
CA3187665A1 (en) 2020-07-06 2022-01-13 Acacia Pharma Ltd Therapy of post-operative nausea and vomiting
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4508047A1 (en) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250157491A (ko) 2022-12-15 2025-11-04 가셔브룸 바이오, 인크. Glp-1 효능제 활성을 갖는 화합물의 염 및 고체 형태
EP4638440A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN120693338A (zh) 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
CN121773120A (zh) 2023-06-30 2026-03-31 加舒布鲁姆生物公司 杂环glp-1激动剂
AR133241A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
EP4743174A1 (en) 2023-07-13 2026-05-20 Aconcagua Bio Inc CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026096926A1 (en) 2024-11-01 2026-05-07 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
NZ570039A (en) 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
JP5714910B2 (ja) * 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
US8138169B2 (en) * 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
ES2665418T3 (es) 2018-04-25
NO2796171T3 (enExample) 2018-06-30
US20200093792A1 (en) 2020-03-26
US20130022689A1 (en) 2013-01-24
US12194022B2 (en) 2025-01-14
KR20130045241A (ko) 2013-05-03
EP2796171A1 (en) 2014-10-29
EA201290833A1 (ru) 2013-09-30
DK2796171T3 (en) 2018-05-07
JP2013522181A (ja) 2013-06-13
SI2796171T1 (en) 2018-05-31
EP2544657B1 (en) 2014-07-16
CY1120170T1 (el) 2018-12-12
WO2011110854A2 (en) 2011-09-15
US9119836B2 (en) 2015-09-01
US9084765B2 (en) 2015-07-21
PT2567690E (pt) 2014-09-03
US10525033B2 (en) 2020-01-07
PL2567690T3 (pl) 2014-11-28
RS53467B (sr) 2014-12-31
US20180353473A1 (en) 2018-12-13
SMT201400127B (it) 2015-05-05
CY1115487T1 (el) 2017-01-04
EP2567690A1 (en) 2013-03-13
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10
EA030335B1 (ru) 2018-07-31
PT2796171T (pt) 2018-04-24
US20250186394A1 (en) 2025-06-12
US20180042896A1 (en) 2018-02-15
DK2567690T3 (da) 2014-08-11
US20150335616A1 (en) 2015-11-26
CN102892407A (zh) 2013-01-23
KR101738201B1 (ko) 2017-05-19
MX370629B (es) 2019-12-18
US10085970B2 (en) 2018-10-02
US9545426B2 (en) 2017-01-17
AU2011225898A1 (en) 2012-10-04
SI2567690T1 (sl) 2014-12-31
US20140147517A1 (en) 2014-05-29
US8686019B2 (en) 2014-04-01
HK1179152A1 (zh) 2013-09-27
SMT201800188T1 (it) 2018-07-17
EP2544657A2 (en) 2013-01-16
US20170087128A1 (en) 2017-03-30
HRP20140745T1 (hr) 2014-09-26
CY1115485T1 (el) 2017-01-04
AU2011225898B2 (en) 2014-07-03
US20220296570A1 (en) 2022-09-22
EP2567690B1 (en) 2014-07-16
CN102892407B (zh) 2016-03-23
MX2019015396A (es) 2020-02-07
JP6279526B2 (ja) 2018-02-14
IL221746A (en) 2017-03-30
GB201004020D0 (en) 2010-04-21
BR112012022746B1 (pt) 2021-09-28
HUE037088T2 (hu) 2018-08-28
ES2496092T3 (es) 2014-09-18
PT2544657E (pt) 2014-09-03
RS57032B1 (sr) 2018-05-31
EP2796171B1 (en) 2018-01-31
DK2544657T3 (da) 2014-08-11
BR112012022746A2 (pt) 2016-07-05
PL2544657T3 (pl) 2014-10-31
US9889118B2 (en) 2018-02-13
JP5886213B2 (ja) 2016-03-16
JP2016028090A (ja) 2016-02-25
MX2012010411A (es) 2012-11-30
US20230144973A1 (en) 2023-05-11
SI2544657T1 (sl) 2014-12-31
ES2496099T3 (es) 2014-09-18
US20210228543A1 (en) 2021-07-29
US20130022688A1 (en) 2013-01-24
NZ602279A (en) 2014-08-29
HRP20140744T1 (hr) 2014-09-26
LT2796171T (lt) 2018-05-10
RS53466B (sr) 2014-12-31
MX388787B (es) 2025-03-20
HRP20180436T1 (hr) 2018-05-04
CA2792392A1 (en) 2011-09-15
SMT201400126B (it) 2015-05-05

Similar Documents

Publication Publication Date Title
US12194022B2 (en) Use of amisulpride as an anti-emetic
AU2014202535B2 (en) The use of amisulpride as an anti-emetic
AU2016216578A1 (en) The use of amisulpride as an anti-emetic
HK1179152B (en) The use of amisulpride for producing an agent in the therapy of nausea, vomiting and retches

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160217

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250304

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250304